NASDAQ : ACLX

Arcellx, Inc.

$115.07 USD

$0.02 (0.02%)

Volume
13.19M
Average Volume
1.45M
Market Capitalization
$6.73B
P/E Ratio
-28.27
Dividend Yield
0.00%
Price Target
$115.00
Year High
$115.13
Year Low
$50.85
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$4.44
Company Overview

NASDAQ

Rami Elghandour

Biotechnology

Healthcare

ACLX

163

US

USD

https://arcellx.com

240 327 0603

03940C100

0001786205

Liquidity Metrics

0.24

4.44

4.44

0.77

0.00

Sales & Valuation

$22.29M

302.09

16.10

-31.67

-3.78

Profitability

-$4.07

-$228.93M

-1027.25%

-1026.95%

-55.42%

-37.90%

P/E Metrics

-28.27

0.44

0.44

Analyst Price Target & Rating

$115.00

$120.00

$82.00

N/A

0/5

18 Analysts

0.06%

Financial Health Scores

17.98

1/9

$357.98M

$603.99M

$201.64M

-$204.65M

Key Metrics (TTM)

$6.75B

302.81

-34.09

4.44

-55.42%

-49.88%

-3.53%

-3.16%

4 days

Company Executives
Name Title
Heba Nowyhed Chief Scientific Officer
Helen Kim VP & Head of Regulatory Affairs
Kate Aiken Chief People Officer
Myesha Lacy Chief Investor & Communications Officer
Neeraj Teotia Chief Commercial Officer
Narinderjeet Singh Chief Technical Officer
Aileen Fernandes Chief Operating Officer
Maryam Abdul-Kareem General Counsel & Chief Legal Officer
Christopher R. Heery Chief Medical Officer
Michelle Lim Gilson Chief Financial Officer
Rami Elghandour Chairman of the Board, Chief Executive Officer & President
Poll Results

No votes yet today — be the first to share your view!

About Arcellx, Inc. (NASDAQ:ACLX) Stock

Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of add ... itional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.

Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel

2026-04-28 08:45:00

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing. The acquisition builds on Kite, a Gilead Company, and.

Frequently Asked Questions

What is the current Arcellx, Inc. (ACLX) stock price?

Arcellx, Inc.(NASDAQ:ACLX) stock price is $115.07 in the last trading session. During the trading session, ACLX stock reached the peak price of $115.13 while $50.85 was the lowest point it dropped to. The percentage change in ACLX stock occurred in the recent session was 0.02% while the dollar amount for the price change in ACLX stock was $0.02.

ACLX's industry and sector of operation?

The NASDAQ listed ACLX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ACLX?

Heba Nowyhed | Chief Scientific Officer
Helen Kim | VP & Head of Regulatory Affairs
Kate Aiken | Chief People Officer
Myesha Lacy | Chief Investor & Communications Officer
Neeraj Teotia | Chief Commercial Officer

How many employees does ACLX have?

Number of ACLX employees currently stands at 163. ACLX operates from 25 West Watkins Mill Road, Redwood City, MD 20878, US.

Link for ACLX official website?

Official Website of ACLX is: https://arcellx.com

How do I contact ACLX?

ACLX could be contacted at phone #240 327 0603 and can also be accessed through its website. ACLX operates from 25 West Watkins Mill Road, Redwood City, MD 20878, US.

How many shares of ACLX are traded daily?

The average number of ACLX shares traded daily for last 3 months was 1.45M.

What is the market cap of ACLX currently?

The market value of ACLX currently stands at $6.73B with its latest stock price at $115.07